在鼻癌的向治疗中,Axl和EGFR双特异性结合性附属体用于向治疗
Saidu Kamara1, He Wen1, Yanru Guo1
1Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Cells
|November 27, 2024
概括
一种新的双特异性附属体,Z239-1907,有效地向和抑制鼻癌 (NPC) 细胞中的Axl和EGFR. 这种双重准的方法显示了改善NPC治疗和早期分子成像诊断的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物技术是生物技术.
背景情况:
- 鼻癌 (NPC) 是一个重大的健康挑战,特别是在东南亚,转移和复发率很高.
- 目前的放射治疗和化疗等治疗方法通常受到晚期诊断的限制,因为缺乏特定的早期检测生物标志物.
- 轴和表皮生长因子受体 (EGFR) 经常在NPC中共同表达,推动瘤进展和治疗耐药性.
研究的目的:
- 开发和评估一种新的双特异性附属体,Z239-1907,用于在鼻癌中同时向和抑制Axl和EGFR.
- 评估Z239-1907作为NPC治疗剂的体外和体内疗效.
- 调查Z239-1907作为早期NPC检测分子成像探针的潜力.
主要方法:
- 产生一个双特异性附属体 (Z239-1907),针对 Axl 和 EGFR.
- 在试验室中对Z239-1907对NPC阳性细胞的抗瘤作用的评估,与单个标附属体相比 (Z_AXL239,Z_EGFR1907).
- 使用NPC异种移植小鼠模型进行体内研究,以评估Z239-1907的瘤生长抑制,生物分布和成像能力.
主要成果:
- 与单个向附属体相比,Z239-1907在体外表现出对NPC细胞的优异抗瘤活性.
- 在体内研究表明,在接受Z239-1907.07治疗的小鼠中,瘤生长受到显著的抑制.
- 在体内,Z239-1907表现出特定和选择性的瘤向,在瘤部位迅速积累,并在24小时内清除,适合分子成像.
结论:
- 双特异性附属体Z239-1907通过同时向鼻癌中的Axl和EGFR提供增强的治疗潜力.
- Z239-1907作为一个有前途的双重功能药物,既可以治疗NPC,也可以用于诊断早期分子成像.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:00Enzyme-linked Receptors
77.3K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.3K